Human Genome Sciences' anthrax treatment ABthrax to face US panel
This article was originally published in Scrip
Executive Summary
The US FDA's anti-infective drugs advisory panel will discuss Human Genome Sciences' (HGS) BLA for its inhalational anthrax treatment ABthrax (raxibacumab injection) on October 27th.